Maegim

Stock search

Search by company name, 6-digit code, or Korean initials (e.g. ㅅㅅㅈㅈ)

☆한국어

KBIO LABS Inc.

케이바이오랩스038530KOSDAQSector: Retail & Consumer Services
₩9990.00%Market cap ₩25.9BAs of Sep 1, 2026 close · updated once daily
Market cap
₩25.9B
#1500 in KOSDAQ
Loss
PER not computable
0.49x
Sector median 0.64x
0.0%
Sector median 0.0%
Trading halted — grade display suspended

This stock is under a trading halt per KRX disclosure. Grade display resumes once trading resumes.

See withholding criteria →View source filing (DART) ↗

This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1-year closing price

Loading closing price history…
 
Low ₩753High ₩2,580
Latest close
Price change by period
1W
4.00%
1M
11.60%
3M
0.80%
1Y
25.10%

Adjusted for 1 price-basis change(s) such as stock splits or reverse splits during the period.

As of the Sep 1, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

1

Financial strength

63.5/100
How much debt does it carry relative to equity?
16.2%
Sector median 78.3%
Sector lowhighTop 11.7% in sector
Can it cover what's due within a year?
520.0%
Sector median 147.9%
Sector lowhighTop 10.5% in sector
How much of revenue becomes profit?
1.7%
Sector median 1.3%
Sector lowhighTop 47.9% in sector
How much did it earn on its own capital?
-6.0%
Sector median 2.1%
Sector lowhighBottom 23.9% in sector

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

90.4/100
How much did revenue grow in a year?
14.1%
Sector median 1.0%
Sector lowhighTop 18.4% in sector
Has it grown steadily over three years?
37.4%
Sector median -1.5%
Sector lowhighTop 4.4% in sector
Did core profits grow in a year?
91.9%
Sector median 7.8%
Sector lowhighTop 13.4% in sector
Are core profits higher than three years ago?
1098.3%
Sector median 3.9%
Sector lowhighTop 2.4% in sector

Financial trend

Revenue

Growth & margin

Revenue growth Operating margin

Year over year — alongside the sector median

This stock Sector median

A factual chart of confirmed annual results from annual reports — the same source as the grading indicators. Not a buy or sell signal.

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

42.0/100
Is the price expensive relative to earnings?
Loss-making (P/E not computable)
Sector median P/E of profitable peers 11.1x · 39% loss-making
Sector lowhighBottom 20.9% in sector
Is the price expensive relative to book value?
0.49x
Sector median 0.64x
Sector lowhighTop 37% in sector

Valuation uses the Sep 1, 2026 close and market cap

4

Shareholder Return

Single-indicator axis30.0/100
Does the company actually pay dividends?
0.0%
Sector median 0.0%
Sector lowhighBottom 30% in sector

Dividends & treasury shares

Treasury shares (FY2025)
217,506 shares (0.1% of shares issued)

Source: annual report (DART) — dividend allocation & total shares

Source filing: annual report (consolidated) — view original ↗

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 1, 2026

Of 9 items: 6 met · 3 not met · 0 not computable

Not metMetNot computable

Positive net income
Whether net income (attributable to owners where available) is above zero.
Not met
-₩3.2B
Positive operating cash flow
Whether cash flow from operations is above zero.
Met
₩8.2B
Return on assets up
Whether net income over beginning total assets rose from the prior year.
Met
-4.8% → -2.7%
Operating cash flow exceeds net income
Whether operating cash flow is greater than net income.
Met
₩8.2B vs -₩3.2B
Liabilities-to-assets ratio down
Whether total liabilities as a share of total assets fell from the prior year.
Not met
8.6% → 13.9%
Current ratio up
Whether current assets over current liabilities rose from the prior year.
Not met
735.2% → 520.0%
Shares outstanding not increased
Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.
Met
115,714,347 → 115,714,347
Operating margin up
Whether operating income over revenue rose from the prior year.
Met
1.0% → 1.7%
Asset turnover up
Whether revenue over beginning total assets rose from the prior year.
Met
0.54x → 0.75x

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (consolidated) — view original ↗

Grade change history

Jul 23, 2026A→B

Methodology version change (v2.0 applied)

Jul 15, 2026AVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Disclosure & financial badges

Factual records determined from public filings and periodic reports by fixed rules — not buy/sell signals.

Negative-evidence group (dilution, loss, dispute)Mixed interpretationPositive-evidence group (shareholder return)Dots classify the disclosure type by the direction of research evidence — not an assessment or investment judgment about this company.

Disclosure event history

Large paid-in capital increase resolved

Disclosed a paid-in capital increase (제3자배정증자) issuing 2,747,253 new shares, equal to 11.9% of shares outstanding before the increase (filed 2026-07-06). View filing ↗

Determined as of 2026-09-01

Recent filings for this stock

Last 120 days · monitored filing types only
Periodic report filedAug 14, 2026Source ↗
Paid-in capital increaseJul 6, 2026Source ↗
Periodic report filedMay 15, 2026Source ↗

View in the filings calendar →